Coverage dated January 20, 2022 to January 25, 2022
New Covid, better treatments: Weapons and tactics used for Omicron, variants to follow
Headline from The Buffalo News, on the newest of 2 developments
If you do get sick with Covid-19 – and your condition goes south – new medications and treatment strategies have continued to improve since the early months of the pandemic.
The Buffalo News's own description from its feed. We collect headlines and these descriptions, not full articles; read the original reporting below.
Developments in this update
2 dated developments, oldest first, newest marked. Each is named by one outlet's own headline; open its reports to see every outlet that covered it.
FDA restricts use of certain monoclonal antibody treatments that don't work against omicron
Headline from FOX 35 Orlando ·
Newest
New Covid, better treatments: Weapons and tactics used for Omicron, variants to follow
As the omicron variant completes its sweep across the U.S., states with scarce supplies of monoclonal antibody therapies continue to use two treatments that federal health officials warn no longer work against the highly contagious version of the virus that causes COVID-19.
U.S. health officials say COVID-19 antibody drugs from Regeneron and Eli Lilly should no longer be used because they don't work against the omicron variant. The Food and Drug Administration
The Food and Drug Administration is expected to significantly restrict the use of a pair of monoclonal antibody treatments for COVID-19 because they are ineffective against the omicron variant, a senior administrati
The U.S. Food and Drug Administration may soon curtail the use of two monoclonal antibody treatments that do not appear to work against the highly contagious Omicron variant.
U.S. health officials say COVID-19 antibody drugs from Regeneron and Eli Lilly should no longer be used because they are unlikely to work against the omicron variant.
The Food and Drug Administration revised authorization of two types of monoclonal antibody treatments for COVID-19 due to growing evidence they do not fight infection of the omicron variant, which accounts for the vast majority of new infections in the United States.
MONDAY, Jan. 24, 2022 (HealthDay News) -- The U.S. Food and Drug Administration may soon curtail the use of two monoclonal antibody treatments that do not appear to work against
U.S. health officials say COVID-19 antibody drugs from Regeneron and Eli Lilly should no longer be used because they don't work against the omicron variant.
MONDAY, Jan. 24, 2022 (healthDay News) -- The U.S. Food and Drug Administration said Monday that it will curtail the use of two monoclonal antibody treatments that do not appear
The Department of Health and Human Services has halted distribution of the medications made by Regeneron Pharmaceuticals and Eli Lilly. Meanwhile, Maine will receive an increased ration of a drug that is effective against omicron.
The Food and Drug Administration (FDA) on Monday significantly restricted the use of a pair of monoclonal antibody treatments for COVID-19 because they are ineffective against the omicron variant.
The FDA curbed the use of two out of three monoclonal antibody treatments. Studies show they're highly unlikely to work against the omicron variant, which is overwhelming hospitals.
If you do get sick with Covid-19 – and your condition goes south – new medications and treatment strategies have continued to improve since the early months of the pandemic.
With the most common monoclonal antibody treatments off the table and new antiviral drugs in short supply, people with COVID-19 have few options when it comes to effective treatments.
WASHINGTON (AP) — COVID-19 antibody drugs from Regeneron and Eli Lilly should no longer be used because they don’t work against the omicron variant that now accounts for nearly all U.S. infections, U.S. health regulators said Monday.
The drugs behind the new pills to treat COVID-19 remain very effective against the omicron variant of the virus in lab tests, according to a new study.
The Food and Drug Administration is curbing the use of two out of three monoclonal antibody treatments because new data shows they aren't effective against the omicron variant.
Identical headlines usually mean shared wire copy. They are counted as separate articles but are not independent confirmation.
